Format

Send to

Choose Destination
Am Heart J. 2016 Sep;179:142-50. doi: 10.1016/j.ahj.2016.06.018. Epub 2016 Jul 6.

Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

Author information

1
University of Louisville, Louisville, KY.
2
Indiana University School of Medicine, Indianapolis, IN.
3
Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN.
4
Cedars-Sinai Heart Institute, Los Angeles, CA.
5
University of Florida College of Medicine, Gainesville, FL.
6
Texas Heart Institute, CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston, TX.
7
Cleveland Clinic Foundation, Cleveland, OH.
8
Wake Forest, School of Medicine, Winston-Salem, NC.
9
Stanford University School of Medicine, Stanford, CA.
10
Houston Methodist DeBakey Heart & Vascular Center, Houston, TX.
11
National Heart, Lung, and Blood Institute, Bethesda, MD.
12
University of Texas School of Public Health, Houston, TX.
13
University of Kansas School of Medicine, Kansas City, KS.
14
University of Texas School of Public Health, Houston, TX. Electronic address: Lemmoye@msn.com.

Abstract

BACKGROUND:

Although several preclinical studies have shown that bone marrow cell (BMC) transplantation promotes cardiac recovery after myocardial infarction, clinical trials with unfractionated bone marrow have shown variable improvements in cardiac function.

METHODS:

To determine whether in a population of post-myocardial infarction patients, functional recovery after BM transplant is associated with specific BMC subpopulation, we examined the association between BMCs with left ventricular (LV) function in the LateTIME-CCTRN trial.

RESULTS:

In this population, we found that older individuals had higher numbers of BM CD133(+) and CD3(+) cells. Bone marrow from individuals with high body mass index had lower CD45(dim)/CD11b(dim) levels, whereas those with hypertension and higher C-reactive protein levels had higher numbers of CD133(+) cells. Smoking was associated with higher levels of CD133(+)/CD34(+)/VEGFR2(+) cells and lower levels of CD3(+) cells. Adjusted multivariate analysis indicated that CD11b(dim) cells were negatively associated with changes in LV ejection fraction and wall motion in both the infarct and border zones. Change in LV ejection fraction was positively associated with CD133(+), CD34(+), and CD45(+)/CXCR4(dim) cells as well as faster BMC growth rates in endothelial colony forming assays.

CONCLUSIONS:

In the LateTIME population, BM composition varied with patient characteristics and treatment. Irrespective of cell therapy, recovery of LV function was greater in patients with greater BM abundance of CD133(+) and CD34(+) cells and worse in those with higher levels of CD11b(dim) cells. Bone marrow phenotype might predict clinical response before BMC therapy and administration of selected BM constituents could potentially improve outcomes of other future clinical trials.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00684060.

PMID:
27595689
PMCID:
PMC5014395
DOI:
10.1016/j.ahj.2016.06.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center